| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters | |------|---------------|--------|---------------|-------------------|------|-------|----------------| | 1 | What are the molecular mechanisms underlying cognitive fluctuations in DLB? | 10 | 7 | 9 | 7 | 33 | Cognitive fluctuations are the most distinctive feature yet have no mechanistic explanation. | | 2 | Why is cholinergic deficiency more severe in DLB than in AD, and what drives visual hallucinations? | 10 | 7 | 8 | 8 | 33 | Cholinergic loss correlates with hallucinations. Understanding this could improve treatment. | | 3 | What determines whether alpha-synuclein pathology presents as DLB vs PD with dementia? | 9 | 7 | 8 | 7 | 31 | Understanding phenotypic divergence could improve diagnosis and treatment. | | 4 | Which biomarkers predict cholinesterase inhibitor response in DLB patients? | 10 | 6 | 8 | 7 | 31 | Only ~30% respond well. Biomarkers would enable personalized treatment. | | 5 | What is the spatial staging pattern of alpha-synuclein in DLB and how does it differ from PD? | 9 | 7 | 7 | 7 | 30 | Different spreading patterns may explain distinct clinical features. |
Tier 2: High-Priority Gaps (Score 25-29)
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters | |------|---------------|--------|---------------|-------------------|------|-------|----------------| | 6 | What is the relationship between RBD, autonomic dysfunction, and disease progression in DLB? | 8 | 7 | 7 | 7 | 29 | Prodromal markers could enable early intervention. | | 7 | How do Lewy body densities correlate with specific clinical symptoms in DLB? | 8 | 7 | 6 | 7 | 28 | Better genotype-phenotype correlations needed. | | 8 | What causes the severe sleep disruption in DLB and how does it affect cognition? | 8 | 6 | 7 | 6 | 27 | Sleep disruption is underappreciated but major contributor to quality of life. | | 9 | Can we develop CSF or blood biomarkers specific for DLB (vs AD or PD)? | 9 | 6 | 8 | 6 | 29 | Accurate differential diagnosis remains challenging. | | 10 | What determines the rapid vs slow progression in DLB? | 8 | 6 | 7 | 6 | 27 | Prognostic biomarkers are needed for clinical trial enrichment. |
Tier 3: Moderate Priority Gaps (Score 20-24)
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters | |------|---------------|--------|---------------|-------------------|------|-------|----------------| | 11 | What is the role of tau co-pathology in DLB clinical heterogeneity? | 7 | 6 | 6 | 7 | 26 | Many DLB cases have AD co-pathology. | | 12 | How do genetic risk factors (GBA, SNCA, APOE) modify DLB phenotype? | 7 | 7 | 6 | 7 | 27 | Genetic modifiers are emerging but poorly understood. | | 13 | Can we develop improved DLB animal models? | 6 | 6 | 6 | 6 | 24 | Current models don't fully recapitulate DLB. | | 14 | What is the optimal treatment sequencing for DLB motor vs cognitive symptoms? | 7 | 5 | 6 | 5 | 23 | Treatment guidelines are empiric, not evidence-based. |
Research Priorities Summary
Cognitive fluctuation mechanisms (Rank 1) - Understand the molecular basis of DLB's most distinctive feature
Cholinergic dysfunction and visual hallucinations (Rank 2) - Link cholinergic loss to specific symptoms
DLB vs PDD phenotype determination (Rank 3) - Understand what causes different outcomes from similar pathology
Treatment response biomarkers (Rank 4) - Enable personalized medicine
[Tirzepatide and Dual GIP/GLP-1 Agonists for Neurodegeneration](/wiki/therapeutics-tirzepatide-dual-gip-glp-agonists-neurodegeneration) — protects_against
[Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — implicated_in
[LC3 Protein](/wiki/proteins-lc3) — implicated_in
Pathway Diagram
The following diagram shows the key molecular relationships involving Dementia with Lewy Bodies Knowledge Gaps discovered through SciDEX knowledge graph analysis: